Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-05-15 Investor Presentation
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation - Investors Meet 2025' and is addressed to stock exchanges and investors. It contains detailed company information, business overview, financial highlights, growth metrics, and strategic outlook. The text references a presentation made at an investor meeting, includes forward-looking statements, and provides extensive data on company operations and market position. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is clearly a presentation intended for investors, consistent with the definition of an Investor Presentation (IP). The document length is substantial (15,000 characters), indicating it is the presentation itself, not just an announcement of it. Therefore, the appropriate classification is Investor Presentation (IP).
2025-05-15 English
Press Release
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Punita Lal as an Additional Director (Non-Executive, Independent) of Lupin Limited. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on management changes and biographical details of the new director. There are no financial statements, earnings data, or regulatory filings beyond the announcement. The document length is 4342 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-05-15 English
Punita Lal Joins Lupin Board as Additional Director.
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Punita Lal as an Additional Director (Non-Executive, Independent) of Lupin Limited. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on management changes, specifically the addition of a new board member, and does not contain financial data, earnings, or detailed reports. The document length is 4342 characters, which is relatively short and typical for an announcement rather than a full report. Therefore, this document fits the category of Board/Management Information (MANG).
2025-05-15 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Abbreviated New Drug Application for Rivaroxaban Tablets. It is addressed to stock exchanges and regulatory bodies under SEBI Listing Regulations, indicating a regulatory disclosure. The content focuses on the announcement of a regulatory approval event rather than financial results, management changes, or detailed financial data. The document length is 4776 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, earnings information, or detailed report content. Therefore, this document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-05-15 English
Lupin Receives Approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for Lupin Limited's Abbreviated New Drug Application for Rivaroxaban Tablets. It is addressed to stock exchanges and regulatory bodies under SEBI Listing Regulations, indicating a regulatory disclosure. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4776 characters, which is relatively short and consistent with a press release. There is no financial data, no detailed financial statements, no voting results, no management changes, or other report types. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories.
2025-05-15 English
Press Release
Annual Report Classification · 95% confidence The document is a press release dated May 14, 2025, from Lupin Limited, reporting audited financial results for the quarter and fiscal year ended March 31, 2025. It includes detailed consolidated financial statements such as income statement highlights, balance sheet highlights, sales mix, operational highlights, and management commentary. The document contains substantive financial data and analysis for both the quarter and full fiscal year, including revenue, EBITDA, profit before tax, profit after tax, segment sales, and R&D investment. It is not merely an announcement of a report or a certification letter but a full financial disclosure. The presence of audited financial results for a full fiscal year and quarter strongly indicates this is an Annual Report or equivalent comprehensive financial report. Given the Indian context and the detailed financial data, this aligns with the definition of an Annual Report (10-K equivalent).
2025-05-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.